Not that anything is wrong with MAC in itselfÐit measures what it purports to measure: the potency of an inhaled anaesthetic to cause absence of a motor response following a noxious stimulus. The fallacy is in equating this with ¢anaesthetic potency¢, since anaesthesia is not a single entity. Anaesthesia is a spectrum of effects on many different neuronal, functional and anatomical substrates. The most important of these effects are, for practical purposes,`unconsciousness' and amnesia, both probably a spectrum of physiological effects. (Immobility, whilst useful, can be achieved by ancillary drugs.) Each of these effects has its own dose±response curve, with its own shape, slope, and EC 50 . MAC only represents the EC 50 for the endpoint of immobility after noxious stimulation. There is nothing to suggest that the ratio between potency to cause immobility and potency to cause unconsciousness is the same for all agentsÐbut this has been assumed for decades, despite evidence to the contrary. A study from the department where MAC originated clearly demonstrated that N 2 O is less potent in causing unconsciousness and amnesia than iso¯urane at equal MAC fractions. At 0.45 MAC iso¯urane, less than 10% of volunteers responded to verbal command, whilst at 0.45 MAC N 2 O all volunteers responded. Conscious memory was prevented by 0.45 MAC iso¯urane, but not completely prevented by even 0.6 MAC N 2 O (the highest concentration tested). A modelled EC 50 for prevention of conscious memory was 0.2 MAC for iso¯urane (95% con®dence interval 0.15±0.25), and 0.5 MAC for N 2 O (0.43±0.55). 4 In effect, N 2 O is less than half as potent an amnesic and hypnotic than was implicitly extrapolated from its potency as an immobilizer. To a lesser degree, this is also true for other agents. For example, halothane is a less potent hypnotic than iso¯urane at equal MAC fractions. According to Eger, MAC awake of halothane is 0.65 MAC, and that of iso¯urane is 0.34 MAC.
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It should come as no surprise that the EC 50 for one effect does not allow extrapolation to other effects, since different phenomena are mediated by different neuroanatomical and functional substrates. Movement in response to a noxious stimulus is largely mediated by the spinal cord.
6 7 Hypnosis and amnesia are largely not. It is well known that any given anaesthetic agent produces a heterogeneous pattern of depression of various areas of the central nervous system, and that these patterns vary between agents. A further possible fallacy is the tacit assumption that the hypnotic effect of N 2 O (small as it is) would be additive to that of a co-administered halogenated vapour. A volunteer study suggested a subadditive effect/partial antagonism on memory suppression. 10 Using the EEG median frequency as an endpoint, however, Ro Èpcke and Schwilden claimed additivity, with each 10% of N 2 O replacing 0.04% of iso¯urane (i.e. approximately a third of its effect on MAC).
11 My interpretation of their data is that they support linearity, but allow no conclusion of additivity. Other authors 12 have found EEG activation with N 2 O, which would suggest a (partially) antagonistic action.
In summary, the`vapour sparing' effect of N 2 O for the endpoints of unconsciousness and amnesia is small, at best in the region of iso¯urane 0.3% for N 2 O 70%, based on ®ndings of the above quoted studies. Whether this reduction in vapour requirement represents any bene®t for the patient, has never been substantiated. I suspect such belief is an atavism from times when anaesthetists worked with chloroform, trichloroethylene, and halothane.
I congratulate Enlund, Edmark, and Revena Ès and their whole department on their decision to abandon the routine use of N 2 O three years ago. They might be bemused to hear that at the same time, their colleagues in the UK spent millions of pounds on upgrading their equipment to prevent the administration of This reference also serves as a good example of a potentially serious, but surprisingly neglected, side-effect of N 2 O. It was clearly shown that N 2 O releases homocysteine into plasma. 13 The homocysteine release seems to be more than a surrogate marker for myocardial ischaemia.
As professionals we have to reconsider our interventions regularly. We are experts in risk-bene®t calculations, but for some curious reason many anaesthetists do not re¯ect over the use of N 2 O. Over all, N 2 O consumption is going down in western European countries, but the trend differs between countries, and certainly within countries (data from the Euroanaesthesia meeting in Glasgow, May 31±June 2, 2003; EAAS2, Scholz J.). Within a narrow health economic perspective, N 2 O seems to be costef®cient (i.e. the drug acquisition cost is low). When considering costs for installation and maintenance of pipes, valves and pressure regulators; the costs of the long list of side-effects; and add its minimal hypnotic sparing effect, then we come to the obvious conclusion: omit the routine use of N 2 O.
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